SCHEMBL4742635

SCHEMBL4742635

Cc1cc(NCc2cc(-c3ccc(-n4ccnc4)c(F)c3)no2)sn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 1/20 0.37
IGF1R P08069 4/20 0.36
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
CYP3A4 P08684 4/20 0.32
CYP2D6 P10635 4/20 0.32
CYP2C9 P11712 4/20 0.32
CYP2C19 P33261 4/20 0.32
CYP1A2 P05177 3/20 0.32
PSEN1 P49768 4/20 0.31
PSEN2 P49810 4/20 0.31
APH1B Q8WW43 4/20 0.31
NCSTN Q92542 4/20 0.31
APH1A Q96BI3 4/20 0.31
PSENEN Q9NZ42 4/20 0.31
POLB P06746 1/20 0.30
MAPT P10636 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
GABRG2 P18507 1/20 0.30
GABRB3 P28472 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4742154 0.82 IGF1R (0.48) IGF1RCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL6429916 0.81 PSEN1 (0.37) IGF1RCYP3A4CYP2C19PSEN1PSEN2
SCHEMBL4679791 0.80 BLM (0.37) BLMIGF1RCYP11B1CYP11B2CYP3A4
SCHEMBL4686139 0.80 POLB (0.42) BLMCYP11B1CYP11B2CYP1A2POLB
SCHEMBL4684193 0.79 POLB (0.54) BLMCYP11B1CYP11B2CYP1A2POLB
SCHEMBL4686141 0.76 ALDH1A1 (0.43) BLMCYP11B1CYP11B2CYP1A2POLB
SCHEMBL4684188 0.74 IGF1R (0.41) IGF1RPOLBMAPTSMN1; SMN2
SCHEMBL14345150 0.73 PSEN1 (0.38) IGF1RCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL14066488 0.69 PSEN1 (0.43) IGF1RCYP3A4CYP2C19PSEN1PSEN2
SCHEMBL4679789 0.65 BLM (0.35) BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1437349-B9 SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS S A L V A T LAB SA (ES) 2008-09-10 EP disclosed
EP-1437349-B1 SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS S A L V A T LAB SA (ES) 2007-08-15 EP disclosed
US-20050014806-A1 Substituted isoxazoles and their use as antibiotics LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2005-01-20 US disclosed
EP-1437349-A1 SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2004-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014806-A1 Substituted isoxazoles and their use as antibiotics XDH, SCO2, HAX1 BLM 2410/4885IGF1R 798/4885CYP11B1 198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.